search
Back to results

Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Besylsartan
Amosartan
Sponsored by
Huons Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

19 Years - 55 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Body Mass Index (BMI) between 18 and 30
  • Healthy as determined by a responsible physician

Exclusion Criteria:

  • History of clinically significant disease
  • Any chronic disease
  • Creatine clearance less than 50ml/min
  • Hypotension (100mmHg/60mmHg)
  • Treatment of barbital type drug within 1 month
  • Administration of herbal medicine within 7 days

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Besylsartan

    Amosartan

    Arm Description

    amlodipine besylate 6.944mg+losartan K 100mg

    amlodipine besylate 7.841mg+losartan K 100mg

    Outcomes

    Primary Outcome Measures

    Change from baseline in blood concentration of Amlodipine
    Detect the change of blood concentration of Amlodipine by LC-MS/MS
    Change from baseline in blood concentration of Losartan
    Detect the change of blood concentration of Losartan by LC-MS/MS

    Secondary Outcome Measures

    Full Information

    First Posted
    July 17, 2015
    Last Updated
    July 20, 2015
    Sponsor
    Huons Co., Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02504606
    Brief Title
    Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
    Official Title
    A Randomized, Open-label, Single Dose, 2-Treatment, 2-Period, 2-Way Crossover Study to Assess Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2015
    Overall Recruitment Status
    Completed
    Study Start Date
    September 2014 (undefined)
    Primary Completion Date
    October 2014 (Actual)
    Study Completion Date
    October 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Huons Co., Ltd.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This clinical trial was evaluated to compare the safety and pharmacokinetics of Besylsartan with Amosartan, which was available commercially after single oral dose in healthy male subjects.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized
    Enrollment
    60 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Besylsartan
    Arm Type
    Experimental
    Arm Description
    amlodipine besylate 6.944mg+losartan K 100mg
    Arm Title
    Amosartan
    Arm Type
    Active Comparator
    Arm Description
    amlodipine besylate 7.841mg+losartan K 100mg
    Intervention Type
    Drug
    Intervention Name(s)
    Besylsartan
    Intervention Description
    Amlodipin besylate 6.944mg+Losartan K 100mg
    Intervention Type
    Drug
    Intervention Name(s)
    Amosartan
    Intervention Description
    Amlodipin besylate 7.841mg+Losartan K 100mg
    Primary Outcome Measure Information:
    Title
    Change from baseline in blood concentration of Amlodipine
    Description
    Detect the change of blood concentration of Amlodipine by LC-MS/MS
    Time Frame
    144 hour
    Title
    Change from baseline in blood concentration of Losartan
    Description
    Detect the change of blood concentration of Losartan by LC-MS/MS
    Time Frame
    10 hour

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    19 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Body Mass Index (BMI) between 18 and 30 Healthy as determined by a responsible physician Exclusion Criteria: History of clinically significant disease Any chronic disease Creatine clearance less than 50ml/min Hypotension (100mmHg/60mmHg) Treatment of barbital type drug within 1 month Administration of herbal medicine within 7 days

    12. IPD Sharing Statement

    Learn more about this trial

    Safety and Pharmacokinetics of Besylsartan Tablet in Healthy Male Subject

    We'll reach out to this number within 24 hrs